Talk:Myalgic encephalomyelitis/chronic fatigue syndrome/NosologyWorkpage

This page exists specifically to discuss and present/edit proposals for the addition of a new section on the main CFS article page:

Proposed structure and content 1

edit

Nosological Developments

edit

The medical classification (nosology) of CFS is subject to ongoing research which is variously focussed upon epidemiology, upon [clinical description]] and upon the establishment of biomarkers.

Epidemiology

edit

Recent work o the epidemiology of CFS is limited to a single study on prevalence in a developing society.

Study Reference Authors URL
Comparative epidemiology of chronic fatigue syndrome in Brazilian and British primary care: prevalence and recognition The British Journal of Psychiatry (2009) 194: 117-122 doi: 10.1192/bjp.bp.108.051813 Hyong Jin Cho et al [1]

Clinical Descriptions

edit

In addition to the operative descriptions employed by national health organisations such as the CDC and NICE, research has produced other clinical descriptions which as yet have not met with general medical consensus:

Study Reference Authors URL
Immunological aspects of chronic fatigue syndrome doi:10.1016/j.autrev.2008.08.003 Lorussoa et al [2]
Conceptual Model for Physical Therapist Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis doi: 10.2522/?ptj.20090047 Physical Therapy April 2010 vol. 90 no. 4 602-614 Davenport et al [3]
Neuropsychological functioning, illness perception, mood and quality of life in chronic fatigue syndrome, autoimmune thyroid disease and healthy participants Psychological Medicine (2009), 39, 1567–1576. doi:10.1017/S0033291708004960 Dickson et al [4]
Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes J Clin Pathol2008;61:730-739 doi:10.1136/jcp.2007.053553 Kerr et al [5]
Can sustained arousal explain the Chronic Fatigue Syndrome? Behavioral and Brain Functions 2009, 5:10 doi:10.1186/1744-9081-5-10 Wyller et al [6]
Chronic fatigue syndrome: illness severity, sedentary lifestyle, blood volume and evidence of diminished cardiac function Clinical Science (2010) 118, (125–135) Hurwitz et al [7]
Chronic fatigue syndrome: aetiology, diagnosis and treatment BMC Psychiatry 2009, 9(Suppl 1):S1 doi:10.1186/1471-244X-9-S1-S1 Fernández et al [8]
Prefrontal cortex oxygenation during incremental exercise in chronic fatigue syndrome DOI: 10.1111/j.1475-097X.2008.00822.x Clinical Physiology and Functional Imaging Neary et al [9]
Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011 Oct;270(4):327-38. doi: 10.1111/j.1365-2796.2011.02428.x Carruthers BM et al [10]

Biomarkers

edit

Successful identification of biomarkers would impact upon future directions in both the epidemiology and in the clinical description of CFS. There is no current general medical consensus on CFS biomarkers however the following have been proposed:

Biomarker Study Reference Author URL
ACCN3 (ASIC3 Moderate Exercise Increases Expression for Sensory, Adrenergic, and Immune Genes in Chronic Fatigue Syndrome Patients But Not in Normal Subjects doi:10.1016/j.jpain.2009.06.003 Light et al [11]
CD8 Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Journal of Translational Medicine 2011, 9:81 Brenu et al [12]
CD26 Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26 PLoS ONE 5(5): e10817. doi:10.1371/journal.pone.0010817 Fletcher et al [13]
Cortisol Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome Psychosomatic Medicine April 1, 2008 vol. 70 no. 3 298-305 doi: 10.1097/?PSY.0b013e3181651025 James et al [14]
FoxP3 Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Journal of Translational Medicine 2011, 9:81 Brenu et al [15]
IFN-g Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Journal of Translational Medicine 2011, 9:81 Brenu et al [16]
IL1 Plasma cytokines in women with chronic fatigue syndrome Journal of Translational Medicine 2009, 7:96 doi:10.1186/1479-5876-7-96, Fletcher et al, [17]
IL1 Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-a, PMN-elastase, lysozyme and neopterin doi:10.1016/j.jad.2011.09.004 | Maesa et al [18]
IL4 Plasma cytokines in women with chronic fatigue syndrome Journal of Translational Medicine 2009, 7:96 doi:10.1186/1479-5876-7-96 Fletcher et al [19]
IL5 Plasma cytokines in women with chronic fatigue syndrome Journal of Translational Medicine 2009, 7:96 doi:10.1186/1479-5876-7-96, Fletcher et al, [20]
IL6 Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis The Journal of Infectious Diseases 2008; 197:1171– 84 DOI: 10.1086/533453 Beverly et al [[21]]
IL10 Moderate Exercise Increases Expression for Sensory, Adrenergic, and Immune Genes in Chronic Fatigue Syndrome Patients But Not in Normal Subjects doi:10.1016/j.jpain.2009.06.003 Light et al [22]
IL10 Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Journal of Translational Medicine 2011, 9:81 Brenu et al [23]
Lipoteichoic acid Plasma cytokines in women with chronic fatigue syndrome Journal of Translational Medicine 2009, 7:96 doi:10.1186/1479-5876-7-96, Fletcher et al, [24]
Lysozyme Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-a, PMN-elastase, lysozyme and neopterin doi:10.1016/j.jad.2011.09.004 | Maesa et al [25]
Na-K-Cl cotransporter(NKCC) Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26 PLoS ONE 5(5): e10817. doi:10.1371/journal.pone.0010817 Fletcher et al [26]
Na-K-Cl cotransporter(NKCC) Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Journal of Translational Medicine 2011, 9:81 Brenu et al [27]
Neopterin Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-a, PMN-elastase, lysozyme and neopterin doi:10.1016/j.jad.2011.09.004 | Maesa et al [28]
P2RX4 Moderate Exercise Increases Expression for Sensory, Adrenergic, and Immune Genes in Chronic Fatigue Syndrome Patients But Not in Normal Subjects doi:10.1016/j.jpain.2009.06.003 Light et al [29]
P2RX5 Moderate Exercise Increases Expression for Sensory, Adrenergic, and Immune Genes in Chronic Fatigue Syndrome Patients But Not in Normal Subjects doi:10.1016/j.jpain.2009.06.003 Light et al [30]
Neuropeptide Y Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome Behavioral and Brain Functions 2010, 6:76 Fletcher et al [31]
Plasma peroxides Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Sci Monit. 2011 Apr;17(4):SC11-5. Maes et al [32]
Neutrophil elastase Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-a, PMN-elastase, lysozyme and neopterin doi:10.1016/j.jad.2011.09.004 | Maesa et al [33]
LDL Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Sci Monit. 2011 Apr;17(4):SC11-5. Maes et al [34]
TNFa Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Journal of Translational Medicine 2011, 9:81 Brenu et al [[35]]
Toll-like receptor Moderate Exercise Increases Expression for Sensory, Adrenergic, and Immune Genes in Chronic Fatigue Syndrome Patients But Not in Normal Subjects doi:10.1016/j.jpain.2009.06.003 Light et al [36]

--In Vitro Infidelium (talk) 15:58, 15 December 2011 (UTC)Reply